• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Dengue - Pipeline Review, Q1 2011 - Product Image

Dengue - Pipeline Review, Q1 2011

  • ID: 1590105
  • March 2011
  • 46 pages
  • Global Markets Direct

Dengue - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Dengue - Pipeline Review, Q1 2011', provides an overview of the Dengue therapeutic pipeline. This report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. 'Dengue - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dengue.
- A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dengue Overview
Therapeutics Development
An Overview of Pipeline Products for Dengue
Dengue Therapeutics under Development by Companies
Dengue Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Dengue Therapeutics - Products under Development by Companies
Dengue Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Dengue Therapeutics Development
United Therapeutics Corporation
Sanofi-Aventis
GlaxoSmithKline plc
Merck & Co., Inc.
Biotron Limited
Alfacell Corporation
AVI BioPharma Inc.
NanoViricides, Inc.
SIGA Technologies, Inc.
Phynova Group Ltd
MacroGenics, Inc.
Canopus BioPharma Incorporated
GenPhar, Inc.
Inviragen, Inc.
Dengue - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Dengue vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CYD Dengue Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
20% Diethyltoluamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dengue Therapeutics - Discontinued Products
Dengue - Featured News
Nov 04, 2010: Sanofi Pasteur’s Dengue Vaccine Enters First Phase III Clinical Study
Oct 25, 2010: Inviragen Initiates DENVax Phase I Clinical Testing In Colombia
May 19, 2010: Inviragen’s Dengue Vaccine to Begin Clinical Testing
Feb 17, 2010: NanoViricides Signs Research And Development Agreement With Dr. Eva Harris’s Laboratory At UC Berkeley For Dengue Program
Aug 25, 2009: Hawaii Biotech Initiates Phase 1 Clinical Trial For Dengue Vaccine
Apr 21, 2009: Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded To Singapore And Vietnam
Apr 21, 2009: Sanofi Pasteur Presents Positive Results Of Tetravalent Dengue Candidate Vaccine
Feb 18, 2009: Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
Sep 12, 2008: NIH Funds SIGA Dengue Antiviral Program
May 21, 2008: SIGA Advances Dengue Antiviral Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dengue, Q1 2011
Products under Development for Dengue – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q1 2011
United Therapeutics Corporation, 2011
Sanofi-Aventis, 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
Biotron Limited, 2011
Alfacell Corporation, 2011
AVI BioPharma Inc., 2011
NanoViricides, Inc., 2011
SIGA Technologies, Inc., 2011
Phynova Group Ltd, 2011
MacroGenics, Inc., 2011
Canopus BioPharma Incorporated, 2011
GenPhar, Inc., 2011
Inviragen, Inc., 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Dengue, Q1 2011
Products under Development for Dengue – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Discovery and Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos